Corporate R&D StrategyNVIDIA's BioNeMo Becomes Pharma's AI Backbone as Novo Nordisk Offloads Parkinson's Risk to AI PartnerSalvado•Jun 27, 2026
Pharmaceutical StrategyNovo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Shutters Internal UnitSalvado•Jun 5, 2026
Corporate StrategyNovo Nordisk Licenses Cell Therapy to AI Spinout as Big Pharma Rewrites Its R&D PlaybookSalvado•Jun 1, 2026
Pharma FinanceNovo Nordisk Licenses Parkinson's Program and Exits Cell Therapy as AI Reshapes Pharma R&DSalvado•May 16, 2026
Corporate StrategyAmgen Merges R&D and AI Under Single Leader as Generative Oncology Race Heats UpSalvado•Apr 30, 2026
Corporate StrategyPharma Giants Deploy AI Infrastructure Through NVIDIA BioNeMo as Sector Shifts to Production-Scale Drug DiscoverySalvado•Apr 18, 2026
Corporate StrategyNVIDIA BioNeMo Platform Secures Partnerships With Lilly, Thermo Fisher in Drug Discovery AI PushSalvado•Apr 14, 2026
Corporate StrategyNVIDIA Partners with Eli Lilly, Thermo Fisher to Build AI Drug Discovery InfrastructureSalvado•Apr 13, 2026
Corporate FinanceNVIDIA's BioNeMo Platform Secures Eli Lilly Partnership as Biotech AI Competition IntensifiesSalvado•Apr 12, 2026
Corporate InnovationNVIDIA Signs Eli Lilly, Thermo Fisher to BioNeMo Platform in Pharmaceutical AI PushSalvado•Mar 29, 2026
Corporate StrategyNVIDIA Expands Biotech AI Infrastructure Through Partnerships with Thermo Fisher and Eli LillySalvado•Mar 25, 2026
Biotech InvestmentNVIDIA's BioNeMo Partnerships With Eli Lilly and Thermo Fisher Signal Institutional Capital Shift Into AI Drug DiscoveryViaNews Editorial Team (Finance)•Feb 18, 2026
AnalysisNVIDIA Targets Drug Discovery Market With AI Infrastructure PushViaNews Editorial Team (Finance)•Feb 15, 2026
